How may off-the-shelf cellular therapies, such as allo and in vivo CARs, change the treatment landscape in #myeloma?馃└
We asked Karlo Perica (@MSKCancerCenter) this question at #iwHRMM25, and here's what he had to say:
馃帴 ow.ly/5tmQ50Xn23x
#MMSM #ImmunoOnc #MultipleMyeloma #CARTCell #HemOnc
馃К At #iwHRMM25, we caught up with Martin Kaiser (@MyMKaiser) of @ICR_London to hear about how the field of #myeloma may move beyond genetics and use RNA profiling to enhance risk detection in the disease.
Watch now:
馃帴 ow.ly/6sls50Xn1PX
#CaGenome #HemOnc #MMSM #HemOnc #MultipleMyeloma
At #iwHRMM25, we filmed a fantastic discussion with leading experts @RossFirestone, @nishjo76, and @AjaiChari, who shared insights into immunotherapy & targeted therapies in high-risk #myeloma.馃└
Watch it now by clicking here:
馃帴 馃憠 ow.ly/2S5e50XjHCv
#MMSM #MultipleMyeloma #HemOnc #ImmunoOnc
馃専Closing up #iwHRMM25 is Binod Dhakal (@bhemato) of @MedicalCollege, with his talk on optimizing the timing of immunotherapy in randomized trials for high-risk #myeloma.
#MMSM #MultipleMyeloma #HemOnc #ImmunoOnc
馃└Robert Orlowski (@Myeloma_Doc) of @MDAndersonNews providing insight into microenvironmental contributions to high-risk disease at #iwHRMM25.
#MMSM #MultipleMyeloma #Myeloma #HemOnc
Martin Kaiser (@MyMKaiser) of @ICR_London at #iwHRMM25: 'Leveraging consistent profiling for single-arm trials with external comparator'
#MMSM #MultipleMyeloma #Myeloma #HemOnc
#iwHRMM25 | We're now hearing about bispecific antibody-based approaches to HRMM from @RaabMarc (@HDMyeloma @DKFZ).
#MMSM #MultipleMyeloma #Myeloma #HemOnc #ImmunoOnc
At #iwHRMM25, Marta Chesi of @MayoClinic provided insight into the preclinical optimization of TCE in #MultipleMyeloma.馃└
#MMSM #Myeloma #HemOnc #ImmunoOnc
Last up in the session on MAF/MAFB disease at #iwHRMM25 is Frank Zhan of @uamshealth, who is highlighting novel biomarkers for guiding the use of immunotherapies.
#MMSM #MultipleMyeloma #Myeloma #HemOnc #ImmunoOnc
